12/28/2023 0 Comments Keynote 189 clinical trialThe WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. “Pembrolizumab plus chemotherapy had a similar OS benefit in the TMB-high and low subgroups.” “Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous NSCLC,”said Dr. Pembrolizumab plus chemotherapy improved overall survival, progression-free survival and objective response rate. TMB as a continuous variable was not significantly associated with overall survival, progression-free survival or objective response rate for pembrolizumab plus chemotherapy or placebo plus chemotherapy. Baseline characteristics and outcomes were generally similar in the TMB-evaluable and total populations. Of the 616 patients enrolled, 293 (48.3%) had evaluable TMB data: 207 for pembrolizumab plus chemotherapy, 86 for placebo plus chemotherapy. The clinical utility of TMB on outcomes was assessed using prespecified TMB cut points of 175 and 150 Mut/. TMB was determined by whole-exome sequencing of tumor and matched normal DNA. Garassino and her colleagues randomized 616 patients 2:1 to pembrolizumab plus chemotherapy or placebo plus chemotherapy. TMB, in concert with PD-L1 expression, has been demonstrated to be a useful biomarker across some cancer types. Tumor mutational burden is a measurement of mutations carried by tumor cells and is a predictive biomarker being studied to evaluate its association with response to immunotherapy. Garassino presented this new data today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Barcelona- Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |